Highlights CRISPR Therapeutics AG

Stocks

CRSP

CH0334081137

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 01:31:34 22/07/2026 am IST			5-day change	1st Jan Change
48.25 ^USD	+2.68%		-4.82%	-8.41%

30/06	CRISPR Therapeutics AG(NasdaqGM:CRSP) added to Russell Small Cap Comp Growth Benchmark	CI
30/06	CRISPR Therapeutics AG(NasdaqGM:CRSP) added to Russell 2500 Growth Benchmark	CI

Highlights

05/05	Earnings Flash (CRSP) CRISPR Therapeutics AG Reports Q1 Revenue $1.5M, vs. FactSet Est of $6.1M	MT
05/05	CRISPR Therapeutics AG Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
13/02	CRISPR Therapeutics AG Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
13/02	Earnings Flash (CRSP) CRISPR Therapeutics AG Reports Q4 Revenue $864,000	MT
22/12	CRISPR Therapeutics Provides Broad Update on Zugocaptagene Geleucel in Autoimmune Disease and Hematologic Malignancies	CI
10/11	CRISPR Therapeutics AG Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
10/11	CRISPR Therapeutics Widens Net Loss in Q3, Revenue Rises	MT
10/11	Earnings Flash (CRSP) CRISPR Therapeutics Posts Q3 Net Loss $1.17 a Share, vs. FactSet Est of $1.25 Loss	MT
10/11	Earnings Flash (CRSP) CRISPR Therapeutics AG Reports Q3 Revenue $889,000, vs. FactSet Est of $9.4M	MT
10/11	CRISPR Therapeutics' Q3 revenue misses estimates	RE
08/11	CRISPR Therapeutics Announces Positive Phase 1 Clinical Data for CTX310	CI
10/25/10	CRISPR Therapeutics Presents New Preclinical Data for CTX460?? Demonstrating in Vivo Gene Correction of Alpha-1 Antitrypsin Deficiency Utilizing Novel SyNTase?? Editing Platform	CI
01/25/01	CRISPR Therapeutics to Present Preclinical Data on Alpha-1 Antitrypsin Deficiency Utilizing Novel Syntase Gene Editing Technology At the European Society of Gene and Cell Therapy 2025 Annual Congress	CI
22/25/22	CRISPR Therapeutics and Sirius Therapeutics Announce First Patient Dosed in Phase 2 Trial of SRSD107 for Thromboembolic Disorders in Europe	CI
05/25/05	CRISPR Therapeutics AG Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
05/25/05	CRISPR Therapeutics Q2 revenue misses estimates, net loss widens	RE
05/25/05	Earnings Flash (CRSP) CRISPR Therapeutics AG Reports Q2 Revenue $0.9M	MT
26/25/26	CRISPR Therapeutics Reports Positive Additional Phase 1 Data for CTX310?? Targeting Angptl3 and Provides Update on in Vivo Cardiovascular Pipeline	CI
20/25/20	CRISPR, Sirius Collaborate on RNA Therapy Targeting Blood Clot Disorders	MT
07/25/07	Earnings Flash (CRSP) CRISPR Therapeutics AG Posts Q1 Revenue $865,000	MT
07/25/07	Earnings Flash (CRSP) CRISPR Therapeutics AG Reports Q1 Loss $1.58 Per Share, vs. FactSet Est of $-1.23	MT
07/25/07	CRISPR Therapeutics AG Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
12/25/12	CRISPR Therapeutics Swings to Q4 Loss, Revenue Falls	MT
12/25/12	CRISPR Therapeutics AG Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024	CI
12/25/12	Earnings Flash (CRSP) CRISPR Therapeutics AG Reports Q4 Revenue $35.7M	MT